The recent introduction of highly effective modulator therapy (HEMT) in CF has shown great promise in restoring some CFTR protein function and thus impacting mucus and the CF lung environment in clinically meaningful ways, improving pulmonary function, BMI, patient-reported quality of life, and decreasing rates of pulmonary exacerbations [149]. The gene discussed is CFTR; the disease is cystic fibrosis.